Evidence of efficacy of OCA for PBC patients
A study published in the Gastroenterology (September 2022) showed that people receiving OCA for primary biliary cholangitis (PBC) in a clinical trial setting had greater transplant-free survival to patients with
Autoantibodies in Primary Biliary Cholangitis
Learn more about how AMA/ANA is used for PBC diagnosis and risk stratification. This article was published in the November 2022 issue of Clinics in Liver Disease Vol 26 IssueSeladelpar – Phase 2 results published
“This study demonstrates the significant anticholestatic effects of seladelpar in patients with PBC who had suboptimally responded to UDCA or were UDCA intolerant. Evidence of seladelpar’s dose-dependent efficacy, safety, and
Elastography is another tool for PBC prognosis
In the present large, international retrospective cohort study, liver stiffness assessed by vibration-controlled transient elastography was validated as one of the strongest predictive factors of poor clinical outcome in PBCCritical shortfalls in PBC management – EASL 2022 – PODIUM PRESENTATION
UK PBC Audit: Critical shortfalls in the management of PBC: results of the first nationwide, population-based study of care delivery across the UK. Presenter: Nadir Abbas Findings from an auditClinical studies of Seladelpar – new analysis
New analyses of clinical studies of Seladelpar were presented during Digestive Disease Week® (DDW) in San Diego on May 23, 2022. The three presentations were: “Seladelpar Treatment of Patients With
Setanaxib TRANSFORM study now enrolling
The purpose of this clinical research study is to evaluate the effects of an investigational product (setanaxib) as a potential additional treatment for PBC. The study is now enrolling in
Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population
“Little is known about PBC affecting subjects with heterogeneous genetic backgrounds [4]. Brazil has a population of a highly admixed origin, with varying proportions of Amerindian, African, and European genetic
Seladelpar RESPONSE study now enrolling
The purpose of this study is to test seladelpar to see if it can improve PBC-related laboratory blood results and symptoms of PBC, such as itching. The goal of the study is